Arthrofibrosis of Knee
Conditions
Keywords
Total Knee Arthroplasty (TKA)
Brief summary
The purpose of this study is to determine the effect of Losartan, an Angiotensin II Receptor Blocker (ARB), on the formation development of arthrofibrosis in patients who have had a primary total knee arthroplasty. This study aims to assess the post-operative range of motion and the incidence of MUA within three months following the index arthroplasty in the treatment arm (losartan) and the control arm.
Interventions
DRUGLosartan
Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
Sponsors
NYU Langone Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Patients are candidates for elective primary total knee arthroplasty for a diagnosis of osteoarthritis or inflammatory arthritis. 2. Patients ≥18 years of age 3. Patients have been medically cleared and scheduled for surgery 4. Patients' primary care physician has verified that the patient can safely take the described dose of Losartan for the duration of the study period.
Exclusion criteria
1. Patients already taking Losartan will not be included in the prospective study 2. Patients already taking an ARB (angiotensin receptor blockers) or other ACE (Angiotensin-converting-enzyme) inhibitor 3. Low blood pressure 4. Currently taking hypertensive medication 5. Revision surgery 6. Surgery for fracture, infection, or malignancy 7. Patients with a diagnosis of post-traumatic arthritis 8. Bilateral, simultaneous surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in range of motion | Baseline, Day 90 |
| Rate of manipulation under anesthesia (MUA) after elective total knee arthroplasty | Day 90 |
Countries
United States
Outcome results
None listed